TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16683215

Group type: EXPERIMENTAL
Intervention: High plasma levels of ACE (> 50 U/L)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: High plasma levels of PAI-1 (> 43 ng/ml)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Thrombolytic agents with high ACE levels
Number of subjects: 184
Study: 15108028

Group type: EXPERIMENTAL
Intervention: Clinical Practice Guidelines for surveillance follow-up
Number of subjects: 0
Study: 11797162

Group type: EXPERIMENTAL
Intervention: Misgav Ladach method
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 172
Study: 9223815

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms/d for 6 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 44
Study: 8387067

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with 50 Gy in 25 daily fractions over 5 weeks
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Cytotoxic therapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 161

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 161
Study: 3293480

Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied during mask ventilation
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cricoid pressure applied during mask ventilation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in difficult to ventilate patients
Number of subjects: 50
Study: 31590692

Group type: EXPERIMENTAL
Intervention: Integrated treatment of Vestibular Rehabilitation (VR) and Cognitive Behaviour Therapy (CBT) with eight sessions after a one-session Brief Intervention Vestibular Rehabilitation (BI-VR)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Brief Intervention Vestibular Rehabilitation (BI-VR)
Number of subjects: 125
Study: 27621048

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide with oxygen (N2O/O2) via nasal mask, titrated to a maximum 70%:30% mixture during the procedure, with pre-procedure placebo pills.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Inhaled O2 during the procedure and 5/325 mg hydrocodone/acetaminophen and 1 mg lorazepam pre-procedure (active control).
Number of subjects: 72
Study: 24100289

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 μg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23480276

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22471971

Group type: EXPERIMENTAL
Intervention: Lifestyle Triple P intervention (14-week program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (brochures, web-based advice, exercise suggestions)
Number of subjects: 0
Study: 20090338

Group type: COMPARATOR
Intervention: 100 U BT injection (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balloon dilation (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Balloon dilation plus 100 U BT injection (Group C)
Number of subjects: 90
Study: 17350629

Group type: EXPERIMENTAL
Intervention: 0.625 mg daily of synthetic conjugated estrogens A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15188350

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg daily subcutaneous injection)
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Overall study population
Number of subjects: 1414
Study: 11467090

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 50
Study: 9669057

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg once daily
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg once daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 7833222

Group type: EXPERIMENTAL
Intervention: Perindoprilat (Pt, 0.67 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 17171860

Group type: EXPERIMENTAL
Intervention: Valvular heart disease (group V)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) (group C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 13
Study: 30106528

Group type: EXPERIMENTAL
Intervention: Two-step 0.454% SnF₂ dentifrice then 3% H₂O₂ whitening gel sequence
Number of subjects: 61

Group type: COMPARATOR
Intervention: Regular 0.76% NaMFP dentifrice control
Number of subjects: 61
Study: 28258664

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (group P)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 96

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 96
Study: 25486333

Group type: EXPERIMENTAL
Intervention: High-dose naringin (1050 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (100 mg talinolol only)
Number of subjects: 10
Study: 23874093

Group type: EXPERIMENTAL
Intervention: SPACE for COPD manual
Number of subjects: 37
Study: 21189384

Group type: EXPERIMENTAL
Intervention: HAI plus systemic therapy with bevacizumab (Bev)
Number of subjects: 73

Group type: COMPARATOR
Intervention: HAI plus systemic therapy without bevacizumab (no Bev)
Number of subjects: 73
Study: 18285602

Group type: EXPERIMENTAL
Intervention: Breast intensity-modulated radiation therapy (IMRT)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard radiotherapy using wedges
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Moist desquamation presence
Number of subjects: 331
Study: 16571277

Group type: EXPERIMENTAL
Intervention: SSLA 200 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group A)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: SSLA 400 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group B)
Number of subjects: 480

Group type: COMPARATOR
Intervention: DSI 20 ml daily (control group)
Number of subjects: 480
Study: 15072499

Group type: EXPERIMENTAL
Intervention: Newer approaches to the management of penile cancer including laser, photodynamic therapy, neoadjuvant therapy, and sentinel node mapping by lympho‐gamma‐scintigraphy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified lymphadenectomy techniques such as the use of ligasure, modified dissection, saphenous vein sparing, and lymphoscintigraphy.
Number of subjects: 0
Study: 10949722

Group type: EXPERIMENTAL
Intervention: Physical therapy and non-steroidal anti-inflammatory drugs as needed
Number of subjects: 139
Study: 8766611

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (Group I)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Enteral nutrition via jejunostomy (Group II)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 22
Study: 1557241

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 25
Study: 3893387

Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Chloramphenicol-gentamicin
Number of subjects: 93
Study: 30979026

Group type: EXPERIMENTAL
Intervention: Including all affective attitude items
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Affective attitude items replaced
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Negatively-worded affective attitude items replaced
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Combination of data from both studies
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Secondary outcomes
Number of subjects: 1623
Study: 30026931

Group type: EXPERIMENTAL
Intervention: Anesthesiology Control Tower (ACT) telemedicine-based decision support system
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Enhanced standard intraoperative care
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Telemedicine-based decision support system (Anesthesiology Control Tower)
Number of subjects: 12000
Study: 27619174

Group type: EXPERIMENTAL
Intervention: Web-based intervention with daily text-messaging (WB + M)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Web-based nutrition intervention only (WBO)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 154
Study: 25345739

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40-120 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 22081056

Group type: EXPERIMENTAL
Intervention: Nurse-delivered symptom management intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Coach-led intervention
Number of subjects: 169
Study: 19421788

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acetaminophen (750 mg PO every 6 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17541072

Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet (SOS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 24
Study: 15385340

Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation (NIPSV)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 150

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 150
Study: 11263636

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 968
Study: 9696467

Group type: EXPERIMENTAL
Intervention: 1 mg of morphine (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (group B)
Number of subjects: 44
Study: 7853327

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Number of subjects: 28
Study: 2756027

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Caloric sweet drinks (sucrose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aspartame plus low glucose maltodextrin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 44
Study: 794003

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31833000

Group type: EXPERIMENTAL
Intervention: CAMBIA® 50 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: IM ketorolac 60 mg
Number of subjects: 23
Study: 31653603

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 0
Study: 27918382

Group type: EXPERIMENTAL
Intervention: Prolonged infusion of meropenem (4 hours)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional infusion of meropenem (30 minutes)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Prolonged infusion of meropenem
Number of subjects: 102
Study: 25432000

Group type: EXPERIMENTAL
Intervention: Nephrology consult with an interdisciplinary team (nephrologist, social worker, clinical ethicist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no additional nephrology consult)
Number of subjects: 0
Study: 23589556

Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 3401

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study: 21488053

Group type: EXPERIMENTAL
Intervention: Caffeine (CAFF) 6 mg kg(‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study: 19581850

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg 90 minutes before surgery)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 16133155

Group type: EXPERIMENTAL
Intervention: Navigator concept
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional navigation setup
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional internal and external alignment jigs
Number of subjects: 40
Study: 12098150

Group type: EXPERIMENTAL
Intervention: Liquid silicone injections (6 injections of 0.2mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 28
Study: 10023509

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study: 7594097

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group I: 0.3 mg/kg body weight bolus, 0.12 mg/kg per h for 24 h)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group II: 0.5 mg/kg bolus, 0.24 mg/kg per h for 24 h)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Heparin (150 IU/kg bolus, 20 IU/kg per h for 24 h)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group I)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (dosage group II)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 61
Study: 2105792

Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy with myosin antibody
Number of subjects: 119

Group type: COMPARATOR
Intervention: 201thallium imaging
Number of subjects: 119

Group type: COMPARATOR
Intervention: Wall motion assessment at the site of antibody uptake
Number of subjects: 119
Study: 6108035

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blocker)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective drug)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All treatments (Propranolol, Metoprolol)
Number of subjects: 7
Study: 29982770

Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in rural South Asia
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in Sri Lanka
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in Bangladesh
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Hypertensive individuals in Pakistan
Number of subjects: 2643

Group type: EXPERIMENTAL
Intervention: Factors associated with CKD
Number of subjects: 2643
Study: 28009680

Group type: EXPERIMENTAL
Intervention: Nonthermal focused ultrasound treatment (3 treatments at 2-week intervals)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control phase (4-week before treatment)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nonthermal focused ultrasound treatment
Number of subjects: 126
Study: 25671826

Group type: EXPERIMENTAL
Intervention: LAM add-on combination therapy (100 mg LAM and 10 mg ADV per day)
Number of subjects: 136

Group type: COMPARATOR
Intervention: ETV monotherapy (0.5 mg ETV per day)
Number of subjects: 136
Study: 24069003

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 69
Study: 21864353

Group type: EXPERIMENTAL
Intervention: Group Medical Consultations (GMCs)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (individual visit)
Number of subjects: 160
Study: 19726905

Group type: EXPERIMENTAL
Intervention: HPV prevention education program
Number of subjects: 63
Study: 17722824

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 30 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (oral Gliguidon or subcutaneous insulin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 54
Study: 15019802

Group type: COMPARATOR
Intervention: 50 mg of oral DHEA daily for 4 weeks
Number of subjects: 6
Study: 11811112

Group type: EXPERIMENTAL
Intervention: Galstena treatment
Number of subjects: 0
Study: 9570260

Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine 125 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7804673

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2972306

Group type: EXPERIMENTAL
Intervention: Nadolol given by mouth 12 h before operation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30480533

Group type: EXPERIMENTAL
Intervention: Mobil‐O‐Graph
Number of subjects: 27

Group type: COMPARATOR
Intervention: SphygmoCor
Number of subjects: 27
Study: 28815789

Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral to community-based treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief intervention and referral
Number of subjects: 0
Study: 25203420

Group type: EXPERIMENTAL
Intervention: Optimized hyperbolic secant (HS) pulse (μ = 4.25, β = 3040 Hz, A0 = 12.3 μT, Δf = 4598 Hz)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Optimized hyperbolic secant (HS) pulse
Number of subjects: 6
Study: 23287079

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with propofol
Number of subjects: 139
Study: 21423020

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannula placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional unguided cannula placement
Number of subjects: 50
Study: 18176118

Group type: EXPERIMENTAL
Intervention: 150 mg of erlotinib under fed conditions
Number of subjects: 40

Group type: COMPARATOR
Intervention: 150 mg of erlotinib under fasting conditions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 mg of erlotinib daily for 8 days under feeding on day 8 after 7 days of fasting
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100 mg of erlotinib daily for 8 days under fasting on day 8 after 7 days of feeding
Number of subjects: 40
Study: 16837430

Group type: EXPERIMENTAL
Intervention: Probio (formula with Lactobacillus johnsonii La1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prebio (formula with fructo-oligosaccharides)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (infant formula)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BF (breastfed infants)
Number of subjects: 90
Study: 12772236

Group type: EXPERIMENTAL
Intervention: Stent delivery system (Boston Scientific NIR, Guidant Tri‐Star/Tetra, Medtronic AVE S670)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Postdilatation with noncompliant balloons
Number of subjects: 256

Group type: COMPARATOR
Intervention: Higher deployment pressures (≥ 12 atm)
Number of subjects: 256
Study: 10203002

Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g intravenous dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 13
Study: 8557786

Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 99
Study: 2018901

Group type: EXPERIMENTAL
Intervention: Local anaesthetic solution injected at body temperature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anaesthetic solution injected at room temperature
Number of subjects: 0
Study: 6125262

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31750800

Group type: EXPERIMENTAL
Intervention: Light-cured tetracaine-based anesthetic gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study: 30084882

Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (PIM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 76
Study: 27988044

Group type: EXPERIMENTAL
Intervention: 60% tea seed oil remover
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tea seed oil remover
Number of subjects: 20

Group type: COMPARATOR
Intervention: Benchmark (olive oil)
Number of subjects: 20
Study: 25791806

Group type: EXPERIMENTAL
Intervention: Liposomal nanoparticle encapsulating prednisolone (LN-PLP) 1.5mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Liposomal nanoparticle encapsulating prednisolone (LN-PLP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24113599

Group type: EXPERIMENTAL
Intervention: Urine culture screening intervention for ESBL-EK; patients colonized or infected were placed in a private room with contact precautions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hospital (no specific intervention mentioned).
Number of subjects: 0
Study: 20410908

Group type: EXPERIMENTAL
Intervention: Thermal warming mattresses
Number of subjects: 39

Group type: COMPARATOR
Intervention: Polyethylene wrap
Number of subjects: 39
Study: 18791483

Group type: EXPERIMENTAL
Intervention: Herbal combination therapy (Hypericum perforatum and Vitex agnus-castus)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study: 17761978

Group type: EXPERIMENTAL
Intervention: Thalidomide (400 mg daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 15051843

Group type: EXPERIMENTAL
Intervention: Prenatal supplementation
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Postnatal intake of supplementation (0.10 to 0.20 MJ/d)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Postnatal intake of supplementation (excess of 0.20 MJ/d)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Postnatal supplementation among women born thin
Number of subjects: 429